Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Jefferies Financial
JEF
5
Amazon
AMZN
AU Stock MarketDetailed Quotes
OPT Opthea Ltd
- 0.600
- 0.0000.00%
20min DelayNot Open Mar 14 16:00 AET
738.75MMarket Cap-1.16P/E (Static)
0.000High0.000Low0Volume0.000Open0.600Pre Close0.00Turnover1.16552wk High0.00%Turnover Ratio1.23BShares0.33552wk Low-0.455EPS TTM471.60MFloat Cap6.765Historical HighLossP/E (Static)786.01MShs Float0.048Historical Low-0.517EPS LYR0.00%Amplitude--Dividend TTM-2.80P/B1Lot Size--Div YieldTTM
About Opthea Ltd Company
Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company geographically operates Australia and United States.
Company Profile
SymbolOPT
Company NameOpthea Ltd
Founded1984
MarketASX
Employees34
Fiscal Year Ends06-30
Address650 Chapel Street Level 4, Suite 0403
CitySouth Yarra
CountryAustralia
Zip Code3141
Phone+61 398260399
Websitehttps://www.opthea.com
Share RegistryCOMPUTERSHARE INVESTOR SERVICES PTY LIMITED
Yarra Falls, 452 Johnston Street, ABBOTSFORD, VIC, AUSTRALIA, 3067
03 9415 4000
Company Executives
- Name
- Position
- Salary
- Dr. Frederic Guerard, Pharm.D.
- Chief Executive Officer
- 1.32M
- Judith J. Robertson
- Chief Commercial Officer
- 715.10K
- Peter F. Lang
- Chief Financial Officer
- 1.16M
- Dr. Megan Baldwin
- Chief Innovation Officer and Executive Director
- 1.36M
- Karen Adams
- Vice President, Finance and Company Secretary
- 466.17K
- Julie Clark
- Senior Vice President, Clinical Development
- --
- Fang Li, PhD
- Senior Vice President, Regulatory
- --
- Mark O Neill
- Vice President, Chemistry, Manufacturing and Controls
- --
- Kevin Bitter
- Vice President, Strategy & Corporate Development
- --
- Bruno Gagnon
- Senior Vice President, Global Clinical Operations
- --
- Dr. John Han
- Vice President, Medical Affairs
- --
- Jeremy M. Levin, D.Phil.,M.B.
- Chairman of the Board
- 309.43K
- Anshul Thakral
- Director
- 103.72K
- Dr. Julia A. Haller, M.D.
- Director
- 170.25K
- Susan Orr
- Independent Director
- 130.26K
- Sujal Shah
- Independent Director
- 16.72K
- Quinton Oswald
- Independent Director
- 135.81K
- Lawrence B. Gozlan
- Independent Director
- 790.52K
Market Insights
Warren Buffett Portfolio Warren Buffett Portfolio
Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry. Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry.
Unlock Now
Discussing
2025 Buffett shareholders' meeting: What's the new buzz in value investing?
🎙️Discussion 1. In the face of market changes, do you prefer to stick with growth stocks or switch to value stocks? 2. Based on the current
Moomoo News Global
Apr 9 20:29
Learning From Buffett: Investing Wisely Amid Market Volatility Triggered by Trump's Tariffs